Table 3.

Overall survival with ipilimumab in phase II clinical trials

Study	Median OS, months [95% CI]a	Overall survival rate, % [95% CI]a
		1-year	2-year	3-year	4-year
CA184-008 (N = 155)
10 mg/kg, previously treated	10.2 [7.6–16.3]	47.2 [39.5–55.1]	32.8 [25.4–40.5]	23.3 [16.7–30.4]	19.7 [13.4–26.5]
CA184-022 (N = 217)
10 mg/kg, previously treated (n = 72)	11.4 [6.9–16.1]	48.6 [36.8–60.4]	29.8 [19.1–41.1]	24.8 [14.8–35.7]	21.5 [11.9–32.0]
3 mg/kg, previously treated (n = 72)b	8.7 [6.9–12.1]	39.3 [28.0–50.9]	24.2 [14.4–34.8]	19.7 [10.7–29.4]	18.2 [9.5–27.6]
0.3 mg/kg, previously treated (n = 73)b	8.6 [7.7–12.7]	39.6 [28.2–51.2]	18.4 [9.6–28.2]	13.8 [6.1–22.5]	13.8 [6.1–22.5]
CA184-007 (N = 115)
Ipilimumab–placebo (n = 57)	19.3 [12.0–34.5]	62.4 [49.4–75.1]	41.8 [28.3–55.5]	34.4 [21.1–48.2]	32.0 [18.9–45.7]
10 mg/kg, treatment-naïve (n = 32)	30.5 [14.0–NR]	71.4 [55.2–87.2]	56.6 [38.4–74.3]	42.5 [23.0–62.0]	37.7 [18.6–57.4]
10 mg/kg, previously treated (n = 25)	14.8 [6.6–20.5]	50.8 [31.5–71.1]	24.2 [8.0–42.8]	24.2 [8.0–42.8]	24.2 [8.0–42.8]
Ipilimumab–budesonide (n = 58)	17.7 [6.8–45.0]	55.9 [42.7–68.8]	41.1 [27.7–54.8]	38.7 [25.2–52.4]	36.2 [22.9–49.9]
10 mg/kg, treatment-naive (n = 21)	45.0 [11.7–NR]	65.9 [45.0–85.7]	57.7 [33.3–81.0]	57.7 [33.3–81.0]	49.5 [23.8–75.4]
10 mg/kg, previously treated (n = 37)	8.5 [6.1–22.7]	49.9 [33.3–66.6]	31.6 [16.5–47.6]	28.4 [13.9–44.2]	28.4 [13.9–44.2]

^aAnalyses include all treated patients in study CA184-008 and all randomized patients in studies CA184-022 and CA184-007.

^bIn the 0.3 and 3 mg/kg dose groups, 33% and 42% of patients, respectively, crossed over to the 10 mg/kg dose group.

NR, not reached.